Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ausra Teiserskiene"'
Autor:
Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significan
Externí odkaz:
https://doaj.org/article/525da2fab1674ea289c10763a6526868
Autor:
Raymond S. McDermott, John Greene, John McCaffrey, Imelda Parker, Sylva Helanova, Anne-Marie Baird, Ausra Teiserskiene, Marvin Lim, Helen Matthews, Olwyn Deignan, John Feeney, Pierre G. Thirion, Stephen P. Finn, Paul J. Kelly
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of a
Externí odkaz:
https://doaj.org/article/9ecf3e519d8642928d0b391548f30aa3
Autor:
Sinead Toomey, Alexander J. Eustace, Joanna Fay, Katherine M. Sheehan, Aoife Carr, Malgorzata Milewska, Stephen F. Madden, Ausra Teiserskiene, Elaine W. Kay, Norma O’Donovan, William Gallagher, Liam Grogan, Oscar Breathnach, Janice Walshe, Catherine Kelly, Brian Moulton, M. John Kennedy, Guiseppe Gullo, Arnold D. Hill, Colm Power, Deirdre Duke, Niamh Hambly, John Crown, Bryan T. Hennessy
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-12 (2017)
Abstract Background The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family muta
Externí odkaz:
https://doaj.org/article/2df2fd828ec74507b4f5c59ad4f1e106
Autor:
Lisa Prior, Niamh M Keegan, Simon J Furney, Janice M Walshe, Giuseppe Gullo, John Crown, M John Kennedy, Diarmuid Smith, John McCaffrey, Catherine M Kelly, Keith Egan, Jennifer Kerr, Mark Given, Niall Sheehy, Peter O'Donovan, Andres Hernando, Ausra Teiserskiene, Imelda Parker, Elaine Kay, Ray McDermott, Maccon M Keane, Seamus O'Reilly, Liam Grogan, Oscar Breathnach, Patrick G Morris, Sinead Toomey, Bryan T Hennessy
Publikováno v:
Cancer Research. 82:P5-16
Background: De novo and acquired resistance to HER2 directed therapy is frequently encountered. Upregulation of the phosphatidylinositol-3-kinase (PI3K) pathway is an important mediator of treatment resistance. This can occur through an activating mu
Autor:
Stephen F. Madden, Colm Power, Janice M. Walshe, Simon J Furney, John Crown, Alex J Eustace, Sinead Toomey, A Hill, William M. Gallagher, Katherine M. Sheehan, Ailis Fagan, Oscar S. Breathnach, Bryan T. Hennessy, Deirdre Duke, Liam Grogan, Bruce Moran, Patrick G. Morris, Norma O'Donovan, Ausra Teiserskiene, Joanna Fay, Elaine W. Kay, Denis M. Collins, K. Egan
Publikováno v:
Breast Cancer Research and Treatment
Background Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymp
Autor:
Niamh M Keegan, Simon Furney, Janice Walshe, Giuseppe Gullo, John Kennedy, Kyran Bulger, John McCaffrey, Catherine M Kelly, Keith Egan, P O'Donovan, Andres Hernando, Ausra Teiserskiene, Imelda Parker, Angela M Farrelly, Aoife Carr, Giulio Calzaferri, Ray McDermott, Maccon M Keane, Liam Grogan, Oscar S Breathnach, Patrick G Morris, Sinead Toomey, Bryan T Hennessy
Publikováno v:
Cancer Research. 80:P1-19
Background Activation of the phosphoinositide -3 kinase (PI3K) pathway is a resistance mechanism to anti-HER2 targeted therapy. This trial was conducted to determine the maximum tolerated dose (MTD) of copanlisib, an oral pan-class I PI3K inhibitor,
Autor:
Pierre Thirion, Paul J. Kelly, Helen Matthews, Anne-Marie Baird, Raymond S. McDermott, John Feeney, Olwyn Deignan, John Greene, Ausra Teiserskiene, John McCaffrey, Imelda Parker, Stephen P. Finn, Sylva Helanova, Marvin Lim
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of a
Autor:
Catherine M. Kelly, Janice M. Walshe, Ausra Teiserskiene, Andres Hernando, S O'Reilly, J.P. Crown, Bryan T. Hennessy, Sinead Toomey, Linda Coate, A Falcon, Oscar S. Breathnach, A. Hassan, Giuseppe Gullo, K. Egan, Manuel Ruiz-Borrego, Liam Grogan, Deirdre O'Mahony, Patrick G. Morris
Publikováno v:
Cancer Research. 79:OT3-06
Background:The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrant activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 p
Autor:
Imelda Parker, Janice M. Walshe, Ray McDermott, Simon J Furney, John McCaffrey, M. John Kennedy, Bryan T. Hennessy, Andres Hernando, M. Keane, Ausra Teiserskiene, Diarmuid Smith, Aoife Carr, Catherine M Kelly, Niamh M Keegan, Mark F. Given, Oscar S. Breathnach, Patrick G. Morris, Liam Grogan, Peter O'Donovan, Jennifer Kerr, Giuseppe Gullo, Sinead Toomey, Elaine W. Kay, K. Egan, Angela M. Farrelly, Giulio Calzaferri
Publikováno v:
Cancers
Volume 13
Issue 6
Cancers, Vol 13, Iss 1225, p 1225 (2021)
Volume 13
Issue 6
Cancers, Vol 13, Iss 1225, p 1225 (2021)
Simple Summary Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to H
Autor:
K. Egan, M Given, Liam Grogan, Andres Hernando, Sinead Toomey, Oscar S. Breathnach, M. Keane, K Bulger, Niamh M. Keegan, Giuseppe Gullo, Patrick G. Morris, CM Kelly, Ausra Teiserskiene, Janice M. Walshe, J Crown, John James Kennedy, J Kerr, Bryan T. Hennessy
Publikováno v:
Cancer Research. 78:OT3-06
Background The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrent activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 p